Behind Closed Doors: FDA Drug Safety Board Will Keep Its Decisions Private
The pharmaceutical industry and other FDA stakeholders should not hold their breath waiting for more details about the agency's Drug Safety Oversight Board recommendations or the extent of internal debate and disagreement at its monthly non-public meetings
You may also be interested in...
FDA's Drug Safety Oversight Board is trying to promote its value to the medical and regulatory communities by highlighting its role in addressing postmarketing safety issues
The FDA advisory committee re-review of cardiovascular safety risks with GlaxoSmithKline's Avandia (rosiglitazone) will not end calls from agency critics to create a separate drug safety center. However, the transparency of internal scientific disputes on display at the July 13-14 meeting and the committee's recommendations could take some ammunition away from those who assert the Center for Drug Evaluation and Research has given short shrift to safety issues
Following the release of FDA's Transparency Task Force report, the agency may want to add an agenda item to its harmonization discussions with EMA